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Applying UK real-world primary care data to predict asthma
attacks in 3776 well-characterised children: a retrospective
cohort study
Steve W Turner 1, Clare Murray2,3, Mike Thomas4,5, Annie Burden6 and David B Price 6,7
Current understanding of risk factors for asthma attacks in children is based on studies of small but well-characterised populations
or pharmaco-epidemiology studies of large but poorly characterised populations. We describe an observational study of factors
linked to future asthma attacks in large number of well-characterised children. From two UK primary care databases (Clinical
Practice Research Datalink and Optimum Patient Care research Database), a cohort of children was identiﬁed with asthma aged
5–12 years and where data were available for ≥2 consecutive years. In the “baseline” year, predictors included treatment step,
number of attacks, blood eosinophil count, peak ﬂow and obesity. In the “outcome” year the number of attacks was determined
and related to predictors. There were 3776 children, of whom 525 (14%) had ≥1 attack in the outcome year. The odds ratio (OR) for
one attack was 3.7 (95% Conﬁdence Interval (CI) 2.9, 4.8) for children with 1 attack in the baseline year and increased to 7.7 (95% CI
5.6, 10.7) for those with ≥2 attacks, relative to no attacks. Higher treatment step, younger age, lower respiratory tract infections,
reduced peak ﬂow and eosinophil count >400/μL were also associated with small increases in OR for an asthma attack during the
outcome year. In this large population, several factors were associated with a future asthma attack, but a past history of attacks was
most strongly associated with future attacks. Interventions aimed at reducing the risk for asthma attacks could use primary care
records to identify children at risk for asthma attacks.
npj Primary Care Respiratory Medicine  (2018) 28:28 ; doi:10.1038/s41533-018-0095-5
INTRODUCTION
There are one million children in the United Kingdom with
asthma1 and six times as many in the United States.2 Asthma
attacks, characterised by acute cough, wheeze and shortness of
breath, are very common and affect approximately 50% of
children with asthma each year.2 Asthma attacks result in
morbidity and occasionally mortality, and also disrupt both the
child’s education and their parent’s economic activity. At least
one-third of healthcare expenditure on childhood asthma is spent
managing asthma attacks.3 Understandably, preventing asthma
attacks is a priority in national asthma guidelines,4–6 but there is
surprisingly little understood about what factors are associated
with future asthma attacks in children.
Good control may be a predictor of future attack,4 and many
children are not optimally controlled,7 but the relationship
between current control and future attacks is relatively weak8 in
part because children are often well controlled for the majority of
the time, but develop attacks with rhinovirus infection. Data from
clinical trials where participants are well-characterised but
relatively small in number ﬁnd that risk factors for asthma attacks
include a recent attack8–10 and clinical measurements such as
blood eosinophilia,10 spirometry (forced expiratory volume in 1 s
(FEV1))
11 and bronchial hyperreactivity.10 Other factors associated
with future asthma attacks in children include young age,10 ethnic
group,8 obesity12 and adherence to asthma medication.13
Pharmaco-epidemiology studies of large unselected populations
of children but who are not characterised in great detail, ﬁnd that
risk factors for asthma attacks, identiﬁed from prescribing or
admission data, include recent treatment with oral corticoster-
oids,14,15 recent admission to hospital with asthma,14 increased
use of bronchodilator medication14 and increased asthma
severity.15 To the best of our knowledge, there are no studies
which describe risk factors for future asthma attacks in the United
Kingdom, where the healthcare setting is different to many
countries. There are also no studies of which we are aware which
relate both routinely acquired outcomes (e.g. prescribing) and
clinical measurements (e.g. lung function) to risk for future asthma
attacks.
Observational studies which use routinely acquired “real-world”
data collected in everyday clinical practice give the opportunity to
study outcomes in many conditions.16 Here we use a large dataset
holding routinely acquired patient information to address the
question “what factors available in primary care practice can be
used to predict asthma attacks in children aged 5–12 years?”
Predictive variables included oral corticosteroid treatment for a
past attack (this was the deﬁnition of an asthma attack in the
present study), current control, severity (as evidence by treatment
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step), age, sex, obesity, peak ﬂow and blood eosinophilia. The
latter was included in light of evidence from children17 and
adults18 that eosinophilia is predictive of future asthma attacks.
Although the Global INitiative for Asthma (GINA) guideline does
not recommend routine measurement of eosinophil count, it does
identify eosinophilia as a risk factor for asthma attacks in children
aged 6–11 years and adolescents.6
RESULTS
Study subjects
There were 3776 children identiﬁed, the mean age was 9.0 years
(SD 2.3) and 57% were male. Figure 1 shows how individuals were
identiﬁed from the whole population. There were 638 children
(16.9%) with ≥1 attack in the baseline year, of whom 178 had ≥2
attacks in the baseline year. In the outcome year, there were 525
(13.9%) children with ≥1 attack(s) including 159 (4.2%) with ≥2
attack(s). Of the 638 patients with ≥1 attack(s) in the baseline year,
240 (38%) had at least one attack during the outcome year. For
the 460 patients with exactly one attack in the baseline year, 143
(31%) had an attack during the outcome year, and for the 178 with
≥2 attacks in the baseline year, there were 97 (54%) who had one
attack in the outcome year. Data were complete for all variables
apart from body mass index (data available in 2037 children) and
peak expiratory ﬂow (PEF) (data available in 2216). Compared to a
population of children from an Optimum Patient Care Research
study who met the same inclusion and exclusion criteria except
the presence of eosinophil data, the 3776 children in the present
study were of similar age and were no more likely to be prescribed
short-acting β-agonists (79 vs. 78%), but had a smaller proportion
of boys (57 vs. 62%), were better controlled (74 vs. 61%) and were
more likely to be prescribed inhaled corticosteroids (70 vs. 65%)
(see Table 1).
Factors detected in the baseline year associated with attack during
the outcome year: univariable analysis
The following factors in the baseline year were associated with
increased risk for asthma attack during the outcome year: young
age, a history of hayfever diagnosis, a history of eczema diagnosis,
eosinophilia, uncontrolled asthma, an asthma attack, consultation
Fig. 1 A consort-style diagram showing how children described in the present study were identiﬁed from the whole population. COPD
chronic obstructive pulmonary disease
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for lower respiratory tract infection, increased use of reliever
medication, higher dose of inhaled corticosteroid and more severe
asthma (as evidenced by Global Initiative for Asthma (GINA)
treatment step) (Table 2). A PEF measurement was obtained
during the baseline year for 2216 children (58.7% of the cohort)
and the mean (SD) PEF reading for 1878 children with no
subsequent asthma attack was 103% (26) and for the 338 with
≥1 subsequent asthma attack was 99% (28), p= 0.020 (Table 2).
Sex and obesity were not associated with altered risk for asthma
attacks (Table 2).
Multivariable analysis
In the multivariable analysis a higher GINA management step,
having any consultation for lower respiratory tract infection, an
asthma attack, the presence of eosinophilia and younger age were
independently associated with increased risk for asthma attack
during the outcome year (Table 3). The % expected PEF was also
predictive of asthma attack in the multivariable analysis of the
sub-group of patients with these data available (odds ratio (OR)
(95% conﬁdence interval (CI)) 0.995 (0.990, 1.000), p= 0.036)
(Table 4).
DISCUSSION
Asthma attacks are common in children and potentially pre-
ventable, and this study was designed to relate a comprehensive
number of factors, which are readily available in primary care, to
Table 1. Comparison of children included in the present study with
children with asthma in primary care
Population in
current study
Reference
population
Mean age (SD), years 9.0 (2.3) 9.0 (2.2)
Gender
% Female (n) 44% (1642) 38% (4213)
% Male (n) 57% (2134) 62% (6812)
Overall asthma control
% Controlled (n) 74% (2768) 61% (6765)
% Uncontrolled (n) 26% (1008) 39% (4265)
Daily SABA dosage (μg)
% on no SABA (n) 21% (777) 22% (2381)
% prescribed 1–100 (n) 12% (465) 51% (5572)
% prescribed 101–200 (n) 28% (1064) 20% (2180)
% prescribed 201–300 (n) 17% (647) 5% (533)
% prescribed 301+ (n) 22% (823) 3% (364)
Average ICS daily dose (BUD
equivalent) (μg)
% prescribed none (n) 30% (1134) 35% (3822)
% prescribed <100 (n) 24% (916) 29% (3234)
% prescribed 101–200 (n) 22% (812) 20% (2217)
% prescribed >200 (n) 24% (914) 16% (1757)
Inclusion criteria for the reference population were doctor diagnosis of
asthma at any time (recorded as a Read code), 1 continuous year of
practice data preceding the index date and atleast one prescription for
asthma therapy within the 2 years preceding the index date (SABA, ICS,
LABA, ICS/LABA combinations, LTRA). Patients were excluded if their record
contained an asthma-resolved Read code or a Read code for COPD or any
chronic respiratory disease other than asthma The index date for each
patient was deﬁned as the date of data extraction for their general
practice. Data for each patient were assessed for 1 year preceding their
index date (the study year); the full period of study ran from 27 January
2009 to 21 March 2013
Table 2. Risk predictors from univariable analysis for at least one
asthma attack deﬁned by American Thoracic Society criteria
Number of future
attacks
Total p Value
0 ≥1
Mean age (SD), years 9.0 (2.3) 8.6 (2.4) 9.0 (2.3) <0.001b
Age group
5–6 years, n (%) 605 (18.6) 139 (26.5) 744 (19.7) <0.001b
7–10 years, n (%) 1559 (48) 244 (46.5) 1803 (47.7)
11–12 years, n (%) 1087 (33.4) 142 (27) 1229 (32.5)
Gender
Female, n (%) 1407 (43.3) 235 (44.8) 1642 (43.5) 0.525b
Male, n (%) 1844 (56.7) 290 (55.2) 2134 (56.5)
IOTF grade
Thin, n (%) 279 (16.5) 53 (15.5) 332 (16.3) 0.941b
Normal, n (%) 929 (54.8) 191 (55.7) 1120 (55)
Overweight, n (%) 303 (17.9) 60 (17.5) 363 (17.8)
Obese, n (%) 183 (10.8) 39 (11.4) 222 (10.9)
Hayfever diagnosis ever
Yes, n (%) 995 (30.6) 189 (36.0) 1184 (31.4) 0.013b
No, n (%) 2256 (69.4) 336 (64.0) 2592 (68.6)
Eczema diagnosis ever
Yes, n (%) 1831 (56.3) 339 (64.4) 2170 (57.5) <0.001b
No, n (%) 1420 (43.7) 186 (35.4) 1606 (42.5)
Eosinophil count (x109/L)
≤0.4, n (%) 1739 (53.5) 225 (42.9) 1964 (52) <0.001b
>0.4, n (%) 1512 (46.5) 300 (57.1) 1812 (48)
Overall asthma control
Controlled, n (%) 2534 (77.9) 234 (44.6) 2768 (73.3) <0.001b
Uncontrolled, n (%) 717 (22.1) 291 (55.4) 1008 (26.7)
Asthma attack in
baseline year
0, n (%) 2853 (87.8) 285 (54.3) 3138 (83.1) <0.001b
1, n (%) 317 (9.8) 143 (27.2) 460 (12.2)
≥2, n (%) 81 (2.5) 97 (18.5) 178 (4.7)
LRTI consultations
resulting in script for
antibiotics
0, n (%) 2910 (89.5) 421 (80.2) 3331 (88.2) <0.001b
1, n (%) 280 (8.6) 82 (15.6) 362 (9.6)
2+, n (%) 61 (1.9) 22 (4.2) 83 (2.2)
GINA management step
0, n (%) 616 (18.9) 52 (9.9) 668 (17.7) <0.001b
1, n (%) 395 (12.2) 47 (9.0) 442 (11.7)
2, n (%) 1726 (53.1) 258 (49.1) 1984 (52.5)
3, n (%) 381 (11.7) 96 (18.3) 477 (12.6)
4, n (%) 125 (3.8) 67 (12.8) 192 (5.1)
5, n (%) 8 (0.2) 5 (1.0) 13 (0.3)
Daily SABA dosage (μg)
None, n (%) 715 (22.0) 62 (11.8) 777 (20.6) <0.001b
1–100, n (%) 410 (12.6) 55 (10.5) 465 (12.3)
101–200, n (%) 925 (28.5) 139 (26.5) 1064 (28.2)
201–300, n (%) 558 (17.2) 89 (17.0) 647 (17.1)
301+, n (%) 643 (19.8) 180 (34.3) 823 (21.8)
Average ICS daily dose
(BUD equivalent) (μg)
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the risk for future asthma attacks in children aged 5–12 years. Our
study considered the largest number of factors previously
described and used a relatively large “real-world” population.
We are not aware of another published material which describes
asthma attack outcomes in a UK population. Our results indicate
that, of all the outcomes collected in this large study, a past
asthma attack (and especially two attacks) is likely to be the best
method to identify children who might beneﬁt from a stratiﬁed
intervention aimed at reducing their risk for future asthma attacks.
Factors other than a past history of attacks which were
associated with increased risk for future asthma attacks included
blood eosinophilia, reduced PEF, lower respiratory tract infection
and younger age, and although these associations were highly
signiﬁcant, they were weakly related to risk for asthma attacks and
therefore not likely to be particuarly helpful in risk analysis.
Current asthma control (as evidenced by short-acting β-agonist
use) was related to future asthma attacks in univariable analysis
but not in the multivariable analysis, and this challenges the
paradigm that in children current control is a useful predictor of
future attacks.4
The majority of the literature describing factors predictive of
asthma attacks in children is based on US populations where the
healthcare system is very different to the United Kingdom, but the
ﬁndings of the current study are nonetheless comparable with the
US literature. For example, in a secondary analysis of data in 285
6–14-year-old trial participants, Covar et al.9 found that those who
received a course of oral corticosteroids for an asthma attack were
at a twofold increased risk of an attack in the following year. A
large database study of 16,250 children with asthma also found a
twofold increase in risk for an attack in the year after a previous
attack.14 In a cohort of 563 6–11 year olds with severe or difﬁcult-
to-treat asthma, Haselkorn et al.8 report that an attack in the
previous 6 months was associated with a threefold increased risk
for future attack. Finally, a study of 14,303 children with asthma
living in the Netherlands also found that a past attack was the
strongest predictor of future attack.15
In contrast with the consistent literature describing the
relationship between past and future asthma attacks in children,
the relationship between asthma control and future attacks is
much less consistent. In our study asthma control (as evidenced
by use of short-acting β-agonist) was associated with increased
risk for attack in the univariable analysis, but this relationship was
not seen in the multivariable analysis, perhaps due to being
subsumed by treatment step. Using more than three SABA
canisters was associated with a 50% increased risk for future attack
in the large database study previously described14, but a
relationship between asthma control (determined by the Chil-
dren’s Asthma Control Test) and future attacks was only present in
one of two other studies.9,19 A disconnect between asthma control
and attack may be explained by different underlying factors, for
example, a rhinovirus infection may commonly lead to an asthma
attack,20 but is not likely to lead to poor control outside the setting
of an attack.
In our study blood eosinophilia at the index date was associated
with increased odds for an asthma attack in the following year, but
the magnitude of the increase was small and is consistent with a
study of 333 5–11 year olds (OR 1.52)17 and 12–80 year olds (OR
1.48),18 and this suggests a common but weak association
between blood eosinophilia and future asthma attacks between
ages 5 and 80 years. We do not believe that blood eosinophilia
should be considered as part of any routine asthma review in
children, but some subgroups (e.g. those with multiple allergies)
may beneﬁt from eosinophil monitoring.
Our study observed a link between reduced PEF and increased
risk of future asthma attack, but the magnitude of the association
was very small. Whilst PEF monitoring is still widely used, current
guidelines do not support its routine use4 and there is good
evidence that routine PEF monitoring does not improve asthma
control.21 There are other objective measures such as FEV1,
22
fractional exhaled nitric oxide23 and exhaled breath condensate19
which may be useful in predicting asthma attacks in children, but
further evaluation of these measurements are required before
they can be routinely applied.
Table 2 continued
Number of future
attacks
Total p Value
0 ≥1
None, n (%) 1032 (31.7) 102 (19.4) 1134 (30.0) <0.001b
<100, n (%) 796 (24.5) 120 (22.9) 916 (24.3)
101–200, n (%) 708 (21.8) 104 (19.8) 812 (21.5)
>200, n (%) 715 (22) 199 (37.9) 914 (24.2)
Percent predicted peak
ﬂow readings (%)
N (% non-missing) 1878 (57.8) 338 (64.4) 2216 (58.7) 0.020a
Mean (SD) 102.89
(25.53)
99.06
(28.24)
102.30
(25.99)
Median (IQR) 101.1
(86.2,
117.7)
98.3 (79.5,
117.3)
100.6
(84.8,
117.6)
Median year at start of
outcome years (IQR)
2007
(2005,
2008)
2007
(2005,
2008)
2007
(2005,
2008)
0.257b
IOTF International Obesity Task Force, GINA Global INitiative for Asthma,
LRTI lower respiratory tract infection
at test
bχ2 test
Table 3. Risk predictors for at least one asthma attack deﬁned by the
American Thoracic Society criteria
Reference
category
Comparison Odds ratio
(95% CI)
p
Value
Overall p
value
Blood eosinophil
count
≤400/µL >400/µL 1.46 (1.20, 1.78) <0.001 <0.001
GINA management
step
0 1/2 1.17 (0.85, 1.62) 0.331 <0.001
3 1.80 (1.23, 2.64) 0.003
4/5 2.77 (1.77, 4.33) <0.001
GP consults for
LRTIs
0 1+ 1.50 (1.15, 1.96) 0.003 0.003
Asthma attack
0 1 3.74 (2.92, 4.80) <0.001 <0.001
2+ 7.72 (5.55,
10.74)
<0.001
Age
Per year of age 0.93 (0.89, 0.97) 0.001
The results are from a multivariable analysis. The following variables were
signiﬁcantly associated with asthma attack in the univariate analyses but
were not signiﬁcant in the multivariate model: hayfever diagnosis ever,
eczema diagnosis ever, overall asthma control, daily short-acting β-agonist
dosage and average inhaled corticosteroid daily dose.
GINA Global INitiative for Asthma, LRTI lower respiratory tract infection
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When interpreting our data it is important to note that not all
children with asthma have their blood eosinophil count measured
and although we have demonstrated that the participants in this
study had only relatively minor differences when compared to a
population of asthmatic children in UK primary care, our results
are likely to be generalisable. The children included in this analysis
had a very similar burden of past asthma attacks compared to
other populations.24,25 What we do not know is why the blood
eosinophilia is being checked; if blood was taken during an
asthma attack, then the relationship between blood eosinophilia
and future attack may be confounded by the very presence of the
initial attack, and this might strengthen any association between
blood eosinophilia and future attacks, but as we have previously
stated, the magnitude of this association was small and of limited
clinical relevance.
A limitation to our study is that we were not able to include an
index of adherence in our analysis and poor adherence is a
potentially modiﬁable risk factor for an asthma attack. A second
limitation is that we did not have an index of asthma control and
we inferred control status from short-acting β-agonist prescription
use. A further limitation is that data for PEF and obesity were
missing for a minority of children and this may have reduced the
power of the analysis, but we do not believe that these missing
data have substantially affected the results since the observed
associations between PEF and obesity and asthma attacks were
respectively weak and non-signiﬁcant.
In summary, we ﬁnd that a past history of asthma attacks is the
best predictor of future attacks, and that blood eosinophilia and
reduced PEF do not add substantially to predicting attacks.
Current guidelines4 recommend that a review in primary care
within two working days of discharge from hospital should
include checking inhaler technique, reviewing the asthma action
plan and modify treatment if required, and a similar intervention
could be applied after an asthma attacks not requiring hospitalisa-
tion. Research is now required to determine whether an early
review after an asthma attack could reduce future asthma attacks.
METHODS
Study design
This was a historic observational cohort study using data from the Clinical
Practice Research Datalink (CPRD, https://www.cprd.com/home/) and
Optimum Patient Care Research Database (OPCRD, http://
optimumpatientcare.org/opcrd/). The use of data was approved by the
Independent Scientiﬁc Advisory Committee of the CPRD and the Trent
Multi-Centre Research Ethics Committee. A steering committee was
involved in a priori deﬁnition of the study methodology (including
statistical analysis plan), review of analyses and interpretation of results.
Data collected during a 12-month period (“baseline year”) were linked to
asthma attacks during the following years (the “outcome year”). The index
date (i.e. the start of the outcome year) was the date when blood
eosinophil count was determined. Variables that were linked to risk of
future asthma attack were selected since they have previously been
associated with asthma attacks in children; also, all but eosinophil count
and peak ﬂow have been associated with the need for more troublesome
asthma (as evidenced by treatment requirement) in this population.26 This
analysis has been registered with European Network of Centres for
Pharmaco-epidemiology and Pharmacovigilance (EUPAS17985) and was
approved by the Anonymised Data Ethics and Protocol Transparency
Committee (approval reference ADEPT 11117).
Data sources
CPRD provides anonymised data from 15% of all general practices in the
United Kingdom, and data were available from 1 January 1999 through
April 2012. OPCRD contains anonymised routine medical record data from
>550 UK practices and data from 1 January 1999 to December 2012 were
used for this study. The characteristics of the study population (i.e.
combined CPRD and OPCRD) were compared to a population of children
with asthma from OPCRD (Table 1).
Inclusion and exclusion criteria
The inclusion criteria were as follows: aged 5–12 years (consistent with the
age range for children in the British Thoracic Society/Scottish Intercollegi-
ate Guideline Network guideline);4 diagnosed asthma (by Read code, see
supplement); 2 years continuous records present. The only exclusion
criterion was the presence of a chronic respiratory condition, for example,
cystic ﬁbrosis.
Table 4. Multivariable analysis of the sub-group of patients with PEF data available describing risk predictors for at least one asthma attack deﬁned
by the American Thoracic Society criteria
Reference category Comparison Odds ratio (95% CI) p Value Overall p value
Blood eosinophil count
≤400/µL >400/µL 1.48 (1.15, 1.91) <0.001 0.002
GINA management step
0 1/2 1.04 (0.67, 1.61) 0.867 <0.001
3 1.65 (1.00, 2.73) 0.050
4/5 2.53 (1.43, 4.46) 0.001
GP consults for LRTIs
0 1+ 1.48 (1.02, 2.14) 0.040 0.003
Asthma attack
0 1 3.72 (2.73, 5.06) <0.001 <0.001
2+ 7.81 (5.18, 11.76) <0.001
% predicted PEF
Per 1% increase 0.995 (0.990, 1.000) 0.036 0.036
Age
Per year of age 0.92 (0.87, 0.97) 0.004 0.004
The results are from a multivariable analysis. The following variables were signiﬁcantly associated with asthma attack in the univariate analyses but were not
signiﬁcant in the multivariate model: hayfever diagnosis ever, eczema diagnosis ever, overall asthma control, daily short-acting β-agonist dosage and average
inhaled corticosteroid daily dose.
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Deﬁnitions used
The American Thoracic Society/European Respiratory Society deﬁnition of
a severe asthma attack27 was used, that is, the occurrence of any of the
following: (i) an asthma-related hospital admission, (ii) an asthma-related
emergency department admission or (iii) a prescription of oral corticoster-
oids for 3–7 days. Overall asthma control was deﬁned as the absence of an
attack (as previously deﬁned) in the previous year and an average daily
dose of ≤200 μg salbutamol/≤500 μg terbutaline.26 The GINA treatment
step and dose of inhaled corticosteroid at the end of the baseline period
were recorded. Peak expiratory ﬂow was standardised using equations
from Rosenthal et al.28 Blood eosinophilia was deﬁned as total eosinophil
count >400 cells/μL. Children were categorised as obese, overweight,
healthy or thin according to the International Obesity Task Force criteria29
using data collected closest to the end of the baseline year.
Statistical analysis
Univariable logistic regression models were used to identify baseline
measures of disease severity, patient demographics and comorbidities
predictive of future attacks. The dichotomous variable indicating an attack
during the outcome period (Yes/No) was used as the dependent variable,
with each measure of disease severity, patient demographic and
comorbidity as an explanatory variable. Those variables which showed
an association (p < 0.05) with future attack were entered into a multi-
variable model which was step-wise reduced to produce a ﬁnal list of non-
collinear predictors of one or more future attacks. Two-sided statistical
tests were used. Linearity was veriﬁed by categorising continuous
variables, and the categorical variable was used in the ﬁnal model if more
appropriate than a continuous variable. Covariates were selected where
the p value from univariate analysis was <0.05; although this stringent cut
off may fail to identify variables associated with the outcome,30 our large
sample size mitigated against this possibility. Results were presented as
ORs with 95% CIs. Standard statistical software was used (SAS version 9.3
and IBM SPSS version 22).
Data availability
The authors are not the custodians of the data and cannot make original
data available but all relevant data are available from the authors. Original
data are available from Clinical Practice Research Datalink (https://www.
cprd.com/home/) and Optimum Patient Care (http://optimumpatientcare.
org/about-us/).
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